Usefulness of discharge standards in outpatients undergoing sedative endoscopy: a propensity score-matched study of the modified post-anesthetic discharge scoring system and the modified Aldrete score

Daisuke Yamaguchi1,2*, Tomohito Morisaki1,3, Yasuhisa Sakata2, Yumi Mizuta1, Goshi Nagatsuma1, Suma Inoue1, Akane Shimakura1, Amane Jubashi1, Yuki Takeuchi1, Kei Ikeda1, Yuichiro Tanaka1, Wataru Yoshioka1, Naoyuki Hino1, Keisuke Ario1, Seiji Tsunada1 and Motohiro Esaki2

Abstract

Background: This study aimed to evaluate the usefulness of discharge standards in outpatients undergoing sedative endoscopy by comparing the modified post-anesthetic discharge scoring system (MPADSS) and the modified Aldrete score.

Methods: We prospectively enrolled 376 outpatients who underwent gastrointestinal endoscopy under midazolam sedation; 181 outpatients were assessed regarding discharge after sedative endoscopy using the MPADSS (group M), and 195 patients were assessed by the modified Aldrete score (group A). The clinical characteristics, types of endoscopy, endoscopic outcomes, and anesthesia outcomes were evaluated between the two groups. We compared discharge score, recovery time, and adverse events using propensity-score matching.

Results: Propensity-score matching created 120 matched pairs. The proportion of patients who had a recovery time within 60 min after endoscopy was significantly higher in group A than that in group M (42.5% versus 25.0%, respectively; \( P < 0.01 \)). The proportion of patients who required > 120 min of recovery time after endoscopy was significantly lower in group A than that in group M (0.0% versus 5.0%, respectively; \( P = 0.03 \)). However, significantly more patients had drowsiness at discharge in group A compared with group M (19.1% versus 5.0%, respectively; \( P < 0.01 \)). There was no significant difference in the adverse event rate within 24 h of discharge between the groups.

Conclusions: Patients assessed by the modified Aldrete score were allowed to discharge earlier than those assessed by the MPADSS. However, a patient’s level of consciousness should be assessed carefully, especially in patients who visit the hospital alone.

Keywords: Discharge, Sedation, Gastrointestinal endoscopy, Outpatients, Discharge time, Adverse events

Introduction

With developments in optical equipment, gastrointestinal endoscopy has become an indispensable technique for screening, diagnosing, and treating a variety of gastrointestinal diseases. However, because the procedure...
requires intubation with a flexible video endoscope, patients sometimes refuse the examination because of fear and anxiety [1, 2]. To improve patients’ acceptability, sedative endoscopy is being used increasingly [3, 4]. Sedation reduces patients’ fear and anxiety regarding endoscopy and also relieves the associated pain and discomfort [5–9]. These benefits can also be expected to lead to earlier detection of gastrointestinal pathologies, such as cancers [3, 10]. As a disadvantage, sedative endoscopy necessitates careful monitoring of a patient’s vital signs and consciousness during and after the procedure [11–13].

In Japan, intravenous sedation is usually performed by the endoscopists and/or nursing staff just before the endoscopy procedure [14–16]. The patients’ vital signs are monitored while they rest for a period of time in the recovery room after sedative endoscopy. Outpatients are allowed to discharge from the hospital when they are considered clinically stable, ready to go home, and able to rest at home [17, 18]. Thus, it is important to have clinically useful and objective discharge criteria to assess a patient’s condition after sedative endoscopy.

Several scoring systems have been proposed for the assessment of patients’ conditions following ambulatory surgery [19–21]. Among them, the modified post-anesthesia discharge scoring system (MPADSS) (see Additional Supplementary Table 1) has been used for the assessment of patients’ conditions following sedative colonoscopy [17, 22, 23]. The modified Aldrete score (see Additional Supplementary Table 2), originally developed to assess post-anesthetic recovery [24], has also been investigated for its usefulness for the assessment of a patient’s condition at discharge after sedative endoscopy [25]. Because a clear discharge standard after sedative endoscopy has not been recommended in the recent guidelines [3], it is necessary to elucidate an appropriate discharge standard after sedative endoscopy.

In this study, we compared the patients’ clinical conditions and adverse events assessed by either the MPADSS or the modified Aldrete score, to determine the best discharge standard for outpatients after sedative endoscopy.

**Methods**

**Patients and ethical issues**

The present study enrolled outpatients who underwent sedative endoscopy at the National Hospital Organization Ureshino Medical Center from two prospective studies that analyzed the usefulness of MPADSS and the modified Aldrete score, respectively, as discharge standards. Outpatients > 20 years of age who underwent esophagogastroduodenoscopy, colonoscopy, or endoscopic ultrasonography under sedation were candidates for the present study. Intravenous sedation was not generally used in patients allergic to midazolam or in pregnant or breastfeeding women, thus excluding these patients. Outpatients who underwent therapeutic endoscopy were also excluded from the present study.

This study was conducted in accordance with the tenets of the Declaration of Helsinki and the guidelines of the Consolidated Standards of Reporting Trials (CONSORT). The study protocol and the consent procedure were approved by the Ethics Review Committee of the National Hospital Organization Ureshino Medical Center (approval number 19–03), and the study was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000037259) on 3 July 2019.

**Sedation and monitoring**

Sedative and analgesic drugs were generally used as follows: An initial bolus of midazolam (3 mg for patients with a bodyweight of < 50 kg and 4 mg for patients with a bodyweight of ≥ 50 kg) was administered through an intravenous catheter. When the patients showed signs of discomfort, restlessness, agitation, and/or a response to verbal commands, 1 mg of midazolam was added as appropriate [5]. Analgesic agents (7.5 mg of pentazocine or 17.5 mg of pethidine hydrochloride) were also used if necessary. Analgesic drugs were selected by each endoscopist, considering the patient’s age or physical condition.

Vital signs, namely blood pressure, heart rate, and blood oxygen saturation were recorded before the induction of sedation. During the endoscopy, vital signs were monitored every 5 min. When oxygen saturation was < 92%, nasal oxygen supplementation (2 L/min) was administered. When a patient’s vital signs fluctuated by ≥ 20% compared with the baseline values, the endoscopic procedure was temporarily stopped until the values returned to baseline values.

Flumazenil, a benzodiazepine antagonist, was administered after the endoscopy as necessary.

**Assessment of the patients’ conditions after sedative endoscopy**

Each patient’s clinical condition after sedative endoscopy was assessed by nurse-administered MPADSS as the discharge standard in 181 outpatients from July 2019 to January 2020 (group M). The patients’ conditions were assessed using a nurse-administered modified Aldrete score in 195 outpatients from July 2020 to December 2020 (group A). In both studies, the patients’ conditions were determined 60 min after the endoscopy. When the MPADSS or the modified Aldrete score reached ≥ 9 (maximum score: 10), patients were allowed to discharge from the hospital. Otherwise, the assessment was
repeated every 30 min. When the patients did not reach a MPADSS or modified Aldrete score $\geq 9$ h after endoscopy, the patient was admitted to the hospital.

**Data collection**

The following patient demographic data were collected by reviewing the patients' electronic clinical records: age, sex, alcohol consumption, smoking habit, body mass index, American Society of Anesthesiologists physical status (ASA-PS) classification, previous history of endoscopy, and comorbidities (including the Charlson comorbidity index score). Endoscopy-related data, namely the types of endoscopy (upper or lower gastrointestinal endoscopy, or endoscopic ultrasonography) and endoscopic outcomes (procedure time, types and amount of sedative, analgesic dose, antagonist, and endoscopist specialty), and peri-procedural adverse events (unstable vital signs indicated by $\geq 20\%$ decrease from the baseline values) were collected by chart review.

After sedative endoscopy, the MPADSS or the modified Aldrete score at 60 min, recovery time, and vital signs before discharge were measured. Any adverse events before discharge and the need for hospitalization were recorded. Adverse events within 24 h after discharge were investigated by telephone questionnaire the day after endoscopy.

**Study endpoints**

The primary endpoint of the present study was the difference in the discharge time after sedative endoscopy between the two groups. The secondary endpoint was the difference in the adverse events rate before discharge, need for hospitalization, and adverse events within 24 h after discharge between the two groups.

**Sample size calculation and statistical analysis**

The sample size was estimated based on previously published results [17] and on the results from the previous data conducted from endoscopy in our hospital from July 2018 to June 2019. Based on these studies, we assumed that the rate of recovery time within 60 min after endoscopy to be 45%. We hypothesized that a difference of 20% in the rate of recovery time between the two groups would constitute a clinically meaningful difference. Assuming a power of 80% and an alpha of 0.025 (one-sided), at least 214 patients (107 patients in each group) would be required in this study. Assuming that 10% of patients could be lost to follow-up, a sample size of 236 patients (118 patients in each group) was planned.

Propensity score matching analysis was used to assess the clinical usefulness of MPADSS and the modified Aldrete score as the discharge criteria. This method was used to adjust for significant differences in the patients' baseline characteristics and to minimize the influence of possible confounding factors [18, 26]. The two groups were matched at a 1:1 ratio (120 patients in each group) with adjustment for seven covariates (age, sex, ASA-PS classification, comorbid malignant diseases, procedure time, mean midazolam dose, use of analgesics) to minimize inherent bias (Fig. 1). These seven covariates were selected based on the opinions of expert endoscopists (DY, TM, NH, YT, and ST). This model yielded a C statistic of 0.754, indicating a preferable ability for the

![Fig. 1. Study flow chart. MPADSS: The modified post-anesthetic discharge scoring system, group M: discharge standard using the modified post-anesthetic discharge scoring system, group A: discharge standard using the modified Aldrete score.](image-url)
comparison between groups M and A. The caliper width of the propensity score matching was 0.20.

Categorical data were expressed as frequency and percentage, and the chi-square test was used to identify differences between the two groups. Normally-distributed numerical data were expressed as mean ± standard deviation, and Student’s t-test was used to determine differences between the two groups. Numerical data with a skewed distribution were expressed as median [interquartile range], and the Mann–Whitney U-test was used for comparisons between the groups. Levels of significance for all comparisons were reported, regardless of statistical significance, as P values or confidence intervals. A P value < 0.05 was considered statistically significant for each test. All statistical analyses were performed with JMP, version 13.2.0 (SAS Institute Inc., Cary, NC, USA).

**Results**

**Characteristics of patients and the propensity-score matched pairs**

The present study included 376 outpatients from the two prospective studies. The patients’ baseline characteristics and endoscopic outcomes are listed in Table 1. When comparing the baseline characteristics between the two groups, sex, ASA-PS classification, and comorbid malignant disease were significantly different between groups M and A. While no significant difference in the type of endoscopy was found between the two groups, endoscopic outcomes were significantly different regarding procedure times, mean doses of midazolam, and the use of an analgesic agent. The rate of adverse events did not differ between the two groups.

Propensity-score matching created 120 matched pairs. After propensity score matching, no difference was found regarding the seven selected covariates between group M and group A (Table 2).

**Study endpoints**

Table 3 shows the results of the comparisons of discharge scores, recovery times, and adverse events before discharge between the two groups. Overall, the MPADSS score 60 min after sedative endoscopy was 9.4 ± 0.9, and the modified Aldrete score was 9.3 ± 1.1.

The proportion of patients who had a recovery time within 60 min after endoscopy was significantly higher in group A than that in group M (42.5% versus 25.0%, respectively; P < 0.01). The proportion of patients who had a recovery time > 120 min after endoscopy was significantly lower in group A than that in group M (0.0% versus 5.0%, respectively; P = 0.03). However, the mean recovery time was comparable between the two groups.

The patients’ vital signs before discharge were not significantly different between the two groups.

Drowsiness was seen more frequently in patients in group A compared with group M as an adverse event before discharge (5.0% versus 19.1%, respectively; P < 0.01), whereas no other adverse event rates differed between the groups. In group M, one patient required hospitalization because of inadequate arousal after sedative endoscopy.

Table 4 shows the comparison of the adverse events within 24 h of hospital discharge between the two
groups. While drowsiness was the most frequent adverse event within 24 h in both groups, the rates of adverse events within 24 h of discharge were not significantly different between the two groups. Most of the adverse symptoms were mild and resolved within 24 h. However, three patients in group M and two patients in group A returned to the hospital within 24 h of discharge for

Table 2  Characteristics before and after propensity-score matching in groups M and A

Before propensity-score matching

|                        | group M (%) | group A (%) | P value | Standardized difference |
|------------------------|-------------|-------------|---------|-------------------------|
| Number of patients (N) | 181         | 195         |         |                         |
| Age (years)            | 64.2 ± 14.3 | 62.8 ± 15.7 | 0.38    | 0.09                    |
| Sex, male              | 53 (29.3%)  | 85 (43.6%)  | <0.01   | 0.30                    |
| ASA-PS classification, I | 170 (93.9%) | 192 (98.5%) | 0.03    | 0.24                    |
| Malignant diseases     | 54 (29.8%)  | 83 (42.6%)  | 0.01    | 0.27                    |
| Procedure time (min)   | 15.8 ± 7.7  | 20.0 ± 11.6 | <0.01   | 0.43                    |
| Mean midazolam dose (mg) | 4.7 ± 1.6  | 4.0 ± 1.5   | <0.01   | 0.45                    |
| Using analgesic agent  | 57 (31.5%)  | 37 (19.0%)  | 0.01    | 0.29                    |

After propensity-score matching

|                        | group M (%) | group A (%) | P value | Standardized difference |
|------------------------|-------------|-------------|---------|-------------------------|
| Number of patients (N) | 120         | 120         |         |                         |
| Age (years)            | 63.4 ± 15.2 | 62.7 ± 15.6 | 0.76    | 0.05                    |
| Sex, male              | 42 (35.0%)  | 35 (29.2%)  | 0.41    | 0.12                    |
| ASA-PS classification, I | 117 (97.5%) | 117 (97.5%) | 1.00    | 0.00                    |
| Malignant diseases     | 43 (35.8%)  | 39 (32.5%)  | 0.68    | 0.07                    |
| Procedure time (min)   | 17.0 ± 8.0  | 16.8 ± 8.6  | 0.81    | 0.02                    |
| Mean midazolam dose (mg) | 4.4 ± 1.6  | 4.3 ± 1.7   | 0.67    | 0.06                    |
| Using analgesic agent  | 29 (24.2%)  | 23 (19.2%)  | 0.43    | 0.12                    |

Table 3  Discharge score, recovery time, and adverse events before discharge in groups M and A

|                        | group M (%) | group A (%) | P value |
|------------------------|-------------|-------------|---------|
| Number of patients (N) | 120         | 120         | 0.38    |
| MPADSS or Modified Aldrete score at 60 min | 9.4 ± 0.9 | 9.3 ± 1.1 | 0.91 |
| Recovery time (min)*   | 60 (60–82.5)| 60 (60–86.3)| <0.01 |
| Recovery time ≤ 60 (min) | 30 (25.0%) | 51 (42.5%) | 0.03 |
| Recovery time ≥ 120 (min) | 6 (5.0%)   | 0 (0%)      | 0.03 |
| Vital signs at discharge |            |             |         |
| Mean systolic pressure (mmHg) | 122.5 ± 18.5 | 121.8 ± 20.4 | 0.78 |
| Mean diastolic pressure (mmHg) | 73.0 ± 13.1 | 70.8 ± 12.4 | 0.19 |
| Mean pulse (/min)       | 67.4 ± 11.0 | 66.4 ± 11.2 | 0.48 |
| Mean oxygen saturation (%) | 97.6 ± 1.7  | 97.5 ± 2.0  | 0.70 |
| Adverse events at discharge |         |             |         |
| Drowsiness              | 6 (5.0%)    | 23 (19.1%)  | <0.01  |
| Bad feeling             | 3 (2.5%)    | 4 (3.3%)    | 1.00   |
| Nausea                  | 0 (0%)      | 2 (1.7%)    | 0.50   |
| Hospitalization         | 1 (0.8%)    | 0 (0%)      | 1.00   |

Results are presented as the number of patients or mean ± standard deviation. MPADSS: the modified post-anesthetic discharge scoring system, group M: discharge standard using the modified post-anesthetic discharge scoring system, group A: discharge standard using the modified Aldrete score.
Table 4 Adverse events within 24h of hospital discharge in groups M and A

|                        | group M (%) | group A (%) | P value |
|------------------------|-------------|-------------|---------|
| Number of patients (N) | 120         | 120         |         |
| Adverse events within 24h |            |             |         |
| Drowsiness              | 38 (31.7%)  | 43 (35.8%)  | 0.59    |
| Bad feeling             | 10 (8.3%)   | 11 (9.2%)   | 1.00    |
| Nausea                  | 9 (7.5%)    | 6 (5.0%)    | 0.60    |
| Vomiting                | 6 (5.0%)    | 4 (3.3%)    | 0.75    |
| Abdominal pain          | 5 (4.2%)    | 3 (2.5%)    | 0.72    |
| Abdominal fullness      | 5 (4.2%)    | 7 (5.8%)    | 0.77    |
| Fever                   | 2 (1.7%)    | 2 (1.7%)    | 1.00    |
| Return to the hospital  | 3 (2.5%)    | 2 (1.7%)    | 1.00    |

Group M: discharge standard using the modified post-anesthetic discharge scoring system, group A: discharge standard using the modified Aldrete score

Discussion

Because the use of sedation can improve the acceptability of gastrointestinal endoscopy, sedative endoscopy has been introduced in many hospitals in Japan [14–16]. Guidelines for sedation in gastroenterological endoscopy have been provided [3]. However, the increasing number of sedative endoscopy procedures has highlighted the requirement for space and personnel for patient recovery. Furthermore, this increase also highlighted the lack of simple and objective criteria to assess patients’ physical conditions for safe discharge from the hospital. Discharge of patients after sedative endoscopy is generally determined in accordance with the comprehensive discretion of the physicians. Cognitive and psychomotor tests are used for the assessment in some institutions; however, these tests are labor-intensive and time-consuming [27–29]. The clinical usefulness of the observer’s assessment of alertness/sedation scale and the Ramsay sedation score for the assessment of sedation levels have been reported previously [30, 31]. However, the validity of these systems for discharge assessment remains uncertain. In the present study, we evaluated the clinical impact of the MPADSS and the modified Aldrete score after sedative endoscopy, considering their suitability as discharge standards after sedative endoscopy. We used these systems because they are widely accepted discharge standards after ambulatory surgery [20, 21, 23–25, 30–33].

In the present study, the subjects were enrolled from the two prospective studies that analyzed the clinical usefulness of the nurse-administered MPADSS or the modified Aldrete score as the discharge standard after sedative endoscopy. Therefore, a significant difference in the patients’ demographics and endoscopy-related factors were found between groups M and A. Thus, we used propensity score matching analysis to adjust for the significant differences in the patients’ baseline characteristics and to minimize the influence of possible confounding factors.

After propensity score matching, although the mean recovery time after sedative endoscopy did not differ between the two groups, more patients in group A were judged to reach the conditions for discharge at 60 min compared with group M. In addition, six patients in group M required more than 2 h to judge that they were safe to discharge. Thus, it can be considered that using the modified Aldrete score shortens the recovery time and uses the endoscopy recovery room more effectively.

In contrast, when comparing adverse events between the two groups, more patients felt drowsiness at discharge in group A compared with group M. This higher rate of drowsiness in group A than that in group M appears to be attributed to the higher number of patients judged safe for discharge within 60 min in group A compared with group M. The difference in the assessment of consciousness level between the two groups could also have contributed to the results. This is because patients judged as arousable upon calling for the consciousness level assessment in the modified Aldrete score can be allowed to discharge if the scores for the remaining assessments are perfect. While the rates of patients who required further observation after discharge were not significantly different between the two groups, a patient’s level of consciousness should be assessed carefully using the modified Aldrete score, especially in patients who visit the hospital alone for sedative endoscopy.

Most of the adverse events within 24 h after discharge in both groups in this study were mild and resolved within 24 h. In this sense, both the MPADSS and the modified Aldrete score can be considered to meet the needs for discharge standards after sedative endoscopy. However, three patients in group M and two patients in group A returned to the hospital within 24 h of discharge for further observation. Therefore, patients and their families should be cautioned regarding possible continuation or deterioration of adverse events even after discharge.

Our study has several limitations. First, this was a single-institution study. Second, this study was not a randomized trial. Well-designed prospective studies are necessary to validate the results of the present study. Third, while the MPADSS and the modified Aldrete score are both simple to use, these systems further observation. One of these patients was admitted to the hospital at the patient’s request.
cannot evaluate all adverse events, such as hypoglycemia. Additionally, the MPADSS includes the item, surgical bleeding, which is inadequate for the assessment of a patient’s condition after sedative endoscopy. No case was defined as positive for hematemesis or bloody stool in the present study.

In conclusion, the modified Aldrete score can be considered more appropriate than the MPADSS as the discharge standard after sedative endoscopy from the viewpoints of the assessment items of the scores and the effective use of the endoscopy recovery room. However, a patient’s level of consciousness should be assessed carefully when using the modified Aldrete score, especially in patients who visit the hospital alone.

Abbreviations
MPADSS: Modified post-anesthesia discharge scoring system; ASA-PS: American Society of Anesthesiologists physical status.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02549-7.

Acknowledgements
The authors thank Dr. Atsushi Imagawa, Imagawa Medical Clinic, Gastroenterology, for clinical advice and assistance with the research design, and Dr. Ayako Takamori, Clinical Research Center, Saga University Hospital, for statistical advice. The authors also thank Ritsuko Ota, RN, Mieko Tonai, RN, Naomi Saito, RN, Furumico Furukawa, RN, Hottomi Soda, RN, Masatosh Daian, RN, and Miwa Furukawa, RN, Ureshino Medical Center, for clinical support. We thank Jane Charbonneau, from Edanz (https://jpedanz.com/ac) for editing a draft of this manuscript.

Authors’ contributions
DY and ME designed the research; DY, TM, YS, GN, SI, AS, AJ, YT, KY, WY, NH, KA, and ST performed the sedative endoscopy, acquired the patients’ data, and made substantial contributions to the conception of the work; DY designed the work; DY analyzed the data, DY, TS, and ME wrote the manuscript; ME was a major contributor to writing the manuscript. All authors read and approved the final version of the manuscript for submission.

All authors have agreed to be personally accountable for their contributions to the work and to ensure that questions related to the accuracy or integrity of any part of the work, even those in which the author was not personally involved, are appropriately investigated and resolved, and that the resolution is documented in the literature.

Funding
No specific grants from any funding agencies in the public, commercial, or not-for-profit sectors were received for this research.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was conducted in accordance with the tenets of the Declaration of Helsinki and the guidelines of the Consolidated Standards of Reporting Trials (CONSORT). The study protocol and the consent procedure were approved by the Ethics Review Committee of the National Hospital Organization Ureshino Medical Center (approval number 19–03). This study was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000372259) on 3 July 2019. Informed consent was obtained from all subjects.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan. 2 Division of Gastroenterology, Department of Internal Medicine, Saga University, Saga 849-8501, Japan. 3 Department of Gastroenterology, Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan.

Received: 2 July 2022 Accepted: 20 October 2022
Published online: 04 November 2022

References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Abraham NS, Fallone CA, Mayrand S, Huang.J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost–outcome study. Am J Gastroenterol. 2004;99:1692–9.
3. Gotoda T, Akamatsu T, Abe S, et al. Guidelines for sedation in gastroenterological endoscopy (second edition). Dig Endosc. 2021;33:21–53.
4. Jin EH, Hong KS, Lee Y, et al. How to improve patient satisfaction during midazolam sedation for gastrointestinal endoscopy? World J Gastroenterol. 2017;23:1098–105.
5. Loftus R, Nugent Z, Graff LA, Schumacher F, Bernstein CN, Singh H. Patient satisfaction with the endoscopy experience and willingness to return in a central Canadian health region. Can J Gastroenterol. 2013;27:259–66.
6. Ko HH, Zhang H, Telford JJ, Enns R. Factors influencing patient satisfaction when undergoing endoscopic procedures. Gastrointest Endosc. 2009;69:883–91.
7. Behrens A, Kreuzmayr A, Manner H, et al. Acute sedation-associated complications in GI endoscopy (ProSed 2 Study): results from the prospective multicentre electronic registry of sedation-associated complications. Gut. 2019;68:445–52.
8. Nass KJ, van Doorn SC, van der Vlugt M, Fockens P, Dekker E. Impact of sedation on the performance indicator of colonic intubation. Endosc. 2021;53:619–26.
9. Forbes N, Chau M, Koury HF, et al. Development and validation of a patient-reported scale for tolerability of endoscopic procedures using continuous sedation. Gastrointest Endosc. 2021;94:103-110.e2
10. Zhou J, Li Z, Ji R, et al. Influence of sedation on the detection rate of early cancer and precancerous lesions during diagnostic upper gastrointestinal endoscopies: a multicenter retrospective study. Am J Gastroenterol. 2021;116:1230–7.
11. Manno M, Desana S, Gabbarini T, et al. Implementation of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) sedation training course in a regular endoscopy unit. Endosc. 2021;53:65–71.
12. Lin OS, La Selva D, Kozarek RA, et al. Nurse-administered propofol continuous infusion sedation: a new paradigm for gastrointestinal procedural sedation. Am J Gastroenterol. 2021;116:710–6.
13. McKenzie P, Fang J, Davis J, et al. Safety of endoscopist-directed nurse-administered balanced propofol sedation in patients with severe systemic disease (ASA class III). Gastrointest Endosc. 2021;94:124–30.

14. Nonaka S, Kawaguchi Y, Oda i, et al. Safety and effectiveness of propofol-based monitored anesthesia care without intubation during endoscopic submucosal dissection for early gastric and esophageal cancers. Dig Endosc. 2015;27:665–73.

15. Yamaguchi D, Yamaguchi N, Takeuchi Y, et al. Comparison of sedation between the endoscopy room and operation room during endoscopic submucosal dissection for neoplasms in the upper gastrointestinal tract. BMC Gastroenterol. 2017;17:127.

16. Takeuchi Y, Yamaguchi D, Yamaguchi N, et al. Propofol sedation in the endoscopy room versus operation room during endoscopic submucosal dissection for gastric tumors: a propensity score-matching analysis. Digestion. 2020;101:450–7.

17. Trevisani L, Cifalà V, Gilli G, Matarese V, Zelante A, Sartori S. Post-anaesthetic discharge scoring system to assess patient recovery and discharge after colonoscopy. World J Gastrointest Endosc. 2013;5:502–7.

18. Kim DB, Kim JS, Huh CW, et al. Propofol compared with bolus and titrated midazolam for sedation in outpatient colonoscopy: a prospective randomized double-blind study. Gastrointest Endosc. 2021;93:201–8.

19. Awad IT, Chung F. Factors affecting recovery and discharge following ambulatory surgery. Can J Anaesth. 2006;53:858–72.

20. Chung F. Discharge criteria—a new trend. Can J Anaesth. 1995;42:1056–8.

21. Palumbo P, Tellan G, Perotti B, Pacilè MA, Vieri F, Illuminati G. Modified PADSS (Post Anesthetic Discharge Scoring System) for monitoring outpatients discharge. Ann Ital Chir. 2013;84:661–5.

22. Rudner R, Jalowiecki P, Kawaewki P, Gonciarz M, Mularczyk A, Petelenz M. Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl, midazolam, and propofol for outpatient colonoscopy. Gastrointest Endosc. 2003;57:657–63.

23. Moncel JB, Nardi N, Wodey E, Povrreau A, Eoffey C. Evaluation of the pediatric post anesthesia discharge scoring system in an ambulatory surgery unit. Paediatr Anaesth. 2015;25:636–41.

24. Aldrete JA, Kroulik D. A postanesthetic recovery score. Anesth Analg. 1970;49:924–34.

25. Willey J, Vargo JJ, Connor JT, Dumot JA, Connell DL, Zuccaro G. Quantitative assessment of psychomotor recovery after sedation and analgesia for outpatient EGD. Gastrointest Endosc. 2002;56:810–6.

26. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.

27. Horisuchi A, Nakayama Y, Fujii H, Katsuyma Y, Ohtomi S, Tanaka N. Psychomotor recovery and blood propofol level in colonoscopy when using propofol sedation. Gastrointest Endosc. 2012;75:506–12.

28. Marshall SI, Chung F. Discharge criteria and complications after ambulatory surgery. Anesth Analg. 1999;88:508–17.

29. Padmaranabhan U, Leslie K, Eer AS, Maruff P, Silber P. Early cognitive impairment after sedation for colonoscopy: the effect of adding midazolam and/or fentanyl to propofol. Anesth Analg. 2009;109:1448–55.

30. Chemik DA, Gillings D, Laine H, Hendler JJ, Silver JM, Davidson AB, et al. Validity and reliability of the observer’s assessment of alertness sedation scale study with intravenous midazolam. J Clin Psychopharmacol. 1990;10:244–51.

31. Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J. 1974;2:656–9.

32. Chung F, Chan WW, Ong D. A post-anesthetic discharge scoring system for home readiness after ambulatory surgery. J Clin Anesth. 1995;7:500–6.

33. Ead H. From Aldrete to PADSS: Reviewing discharge criteria after ambulatory surgery. J Perianesth Nurs. 2006;21:259–67.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.